Olodaterol Hydrochloride

盐酸奥达特罗

Report date: 2026/03/23 20:03:44
NME

Base Information

Drug NameOlodaterol Hydrochloride
Drug Alias Name奥洛特罗olodaterolum奥达特罗olodaterolStriverdi Respimat +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBeta-2 adrenergic receptor agonists
TargetsBeta-2 adrenergic receptor
Therapy Area/IndicationsEmphysemaXerophthalmiaPulmonary Disease, Chronic Obstructive +[6] 
Global Approved IndicationsEmphysemaPulmonary Disease, Chronic ObstructiveBronchitis, Chronic
Approved Indications in ChinaPulmonary Disease, Chronic Obstructive
Original Approved Country/TerritoryUnited Kingdom
Original Approved Date2013/10/10
Country/TerritoryCzechiaBelgiumBulgaria +[47] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. KgSanten Pharmaceutical Co LtdBoehringer Ingelheim International Gmbh
Inactive CompaniesN/A
Active IndicationsEmphysemaXerophthalmiaPulmonary Disease, Chronic Obstructive +[4] 
Inactive IndicationsAsthmaLiver Diseases

Other Information

ATC CodeR03AC19
Related LinksWikipediaDrugBankKEGG